It sounded like there are many exciting and positive developments on the horizon (The European approvals keep coming). The Viropharma incident was the only negative; it will be steady growth going forward....the Pancreatic cancer program sounds very exciting to say the least and the relationships with Baxter and Pfizer are very solid to date.
I am interested on other thoughts regarding the PPS; seems to be undervalued at this time?
Very undervalued at this point IMO. Per Frost on CC, paraphrased, "We remain in constant contact with all regulatory agencies regarding all our programs and no concern has been expressed about any current program."
Mgt was very upbeat and positive. Outlook seems bright and PPS seems undervalued. Bought back a new position today going into earnings. Shorts will start to cover IMO due to catalysts moving forward and potential for Mabthera CHMP approval in August.
Lots of biotechs getting beat up heading into earnings because no one wants to get caught by surprise. Happened with ARNA the other day as well and it was green today and moving off it's lows.